Skip to content
Clinical Trials – home
GreeceBack to Greece

Clinical trials in Kalamaria – page 2

740 clinical trials in Kalamaria, Greece. Every trial is listed in the EU Clinical Trials Register and updated daily.

GreeceOur site in GreeceΚλινικεσΔοκιμεσ.gr(opens in a new tab)
Kalamaria at a glance
740
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

740 trials in Kalamaria

Open in trial search

Phase 2 Study of Nemolizumab for Skin Thickening in Adults with Systemic Sclerosis

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Nemolizumab
  • Sponsor:Galderma S.A.

A Phase 3 Randomized Study of mRNA‑4157 plus Pembrolizumab as Adjuvant Therapy in Patients with Completely Resected Stage I Non‑Small Cell Lung Cancer

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:MRNA-4157
  • Sponsor:Merck Sharp & Dohme LLC

A Phase 3 Study of Efimosfermin Alfa to Assess Safety and Tolerability in Adults with F2‑F3 Stage Metabolic Dysfunction‑Associated Steatohepatitis (MASH)

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Efimosfermin alfa
  • Sponsor:Glaxosmithkline Research & Development Limited

Phase 3 study of ZL-1310 versus topotecan hydrochloride in patients with relapsed small cell lung cancer

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:ZL-1310
  • Sponsor:Zai Lab (US) LLC

Study of PF-07275315 versus placebo for efficacy and safety in adults with moderate-to-severe chronic obstructive pulmonary disease (COPD)

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:PF-07275315
  • Sponsor:Pfizer Inc.

Hidradenitis

Recruiting

Long-term Safety and Efficacy of Remibrutinib in Adults with Moderate to Severe Hidradenitis Suppurativa

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Orelabrutinib
  • Sponsor:Zenas Biopharma (USA) LLC

Obesity+2

Recruiting

A study to evaluate the effects of zenagamtide on weight and pain in patients with overweight or obesity and knee osteoarthritis

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Zenagamtide
  • Sponsor:Novo Nordisk A/S

Obesity+2

Recruiting

A study to evaluate the efficacy and safety of zenagamtide in people with overweight or obesity and knee osteoarthritis

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Zenagamtide
  • Sponsor:Novo Nordisk A/S

A study to evaluate the long-term safety and effectiveness of barzolvolimab in patients with chronic spontaneous urticaria

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Barzolvolimab
  • Sponsor:Celldex Therapeutics Inc.

Study of sotorasib, panitumumab and a drug combination for patients with metastatic colorectal cancer with KRAS p.G12C mutation.

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years
  • Substances:Bevacizumab
  • Sponsor:Amgen Inc.

A study to evaluate the effectiveness and safety of remibrutinib in patients with secondary progressive multiple sclerosis

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

Other cities in Greece

The busiest research cities in the country

All 48 cities in Greece

Clinical research in Kalamaria

What the registry says about research in the country

01 Cardiovascular Research

Innovative clinical trials focusing on atherosclerotic cardiovascular disease in patients with end-stage kidney disease are being conducted. The research aims to evaluate novel therapeutic approaches for patients undergoing dialysis treatment.

  • Cardiovascular Outcomes
  • Inflammatory Biomarkers
  • Dialysis Patient Care

These studies specifically examine the effectiveness of targeted treatments in reducing C-reactive protein levels, a key marker of inflammation in cardiovascular disease among dialysis patients.

02 Nephrology Studies

Current research explores the intersection of kidney disease and cardiovascular complications, with a particular focus on patients receiving maintenance dialysis treatment.

  • End-Stage Kidney Disease Management
  • Cardiovascular Risk Assessment
  • Treatment Response Monitoring

The trials investigate intravenous therapeutic options designed to improve outcomes for patients with complex cardiovascular and renal conditions.

03 Inflammatory Disease Research

Specialized studies are evaluating the role of inflammation markers in cardiovascular complications among dialysis patients, testing innovative therapeutic approaches.

  • Inflammatory Biomarker Analysis
  • Disease Progression Monitoring
  • Treatment Response Assessment

This research aims to advance our understanding of inflammation's role in cardiovascular disease among patients with kidney failure.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.